Option chain shows key data for Chugai Pharmaceutical's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Chugai Pharmaceutical.

Chugai Pharmaceutical (OTC:CHGCF) Stock, Option Chain

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and covid-19 patients.

News

Penny Stocks

Health Care

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

ABBV

ABOS

ALXO

ANVS

ARGNF

CHGCF

HALO

RHHBY

Halozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which is produced using the company&#39;s proprietary ENHANZE manufacturing methods.

Halozyme&#39;s ENHANZE Product Gets New Patent Grant in EU

CHUGAI PHARMACEUTICAL by Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co Ltd

Chugai Pharmaceutical

Comments

Chugai Pharmaceutical

Chugai Pharmaceutical (CHGCF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga